Susan Dana Jones Disposes Shares and Stock Options in Tourmaline Bio, Inc. Following Merger

Susan Dana Jones, Chief Technology Officer of Tourmaline Bio, Inc., disposed of 19,782 shares of common stock and 180,993 stock options as part of the company's merger with Novartis AG. The merger, completed on October 28, 2025, involved a cash tender offer of $48.00 per share. The stock options were canceled and converted into cash based on the difference between the merger consideration and the exercise price of the options. This transaction resulted in Jones no longer holding any shares or stock options in Tourmaline Bio, Inc.